Spark Therapeutics Announces Pricing and First-of-their-kind Patient Access Programs

Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced three new payer programs: an outcomes-based rebate arrangement with a long-term durability measure, an innovative contracting model and a proposal to CMS under which payments for LUXTURNA™ (voretigene neparvovec-rzyl) would be made over time. The price of the therapy is to be set at $ 850 000 per patient.

Read more at Spark Therapeutics website.